P21.07 Immune-Related Adverse Events with Durvalumab Consolidation in a Real-World Cohort of Patients with Non–Small Cell Lung Cancer (NSCLC)

Autor: Montenegro, G. Bravo, Serzan, M., Belouali, A., Sackstein, P., Chen, K., Rao, S., Veytsman, I., Madhavan, S., Liu, S., Kim, C.
Zdroj: In Journal of Thoracic Oncology March 2021 16(3) Supplement:S366-S366
Databáze: ScienceDirect